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OBJECTIVES The aim of this study was to assess whether endogenous accumulation of adenosine, induced
by low-dose dipyridamole infusion, protects from exercise-induced ischemia.
BACKGROUND Adenosine is a recognized mediator of ischemic preconditioning in experimental settings.
METHODS Ten patients (all men: mean age 63.4 6 7.3 years) with chronic stable angina, angiographi-
cally assessed coronary artery disease (n 5 7) or previous myocardial infarction (n 5 3) and
exercise-induced ischemia underwent on different days two exercise-stress echo tests after
premedication with placebo or dipyridamole (15 mg in 30 min, stopped 5 min before testing)
in a double-blind, placebo controlled, randomized crossover design.
RESULTS In comparison with placebo, dipyridamole less frequently induced chest pain (20% vs. 100%,
p 5 0.001) and .0.1 mV ST segment depression (50% vs. 100%, p , 0.05). Wall motion
abnormalities during exercise-stress test were less frequent (placebo 5 100% vs. dipyrida-
mole 5 70%, p 5 ns) and significantly less severe (wall motion score index at peak stress:
placebo 5 1.55 6 0.17 vs. dipyridamole 5 1.27 6 0.2, p , 0.01) following dipyridamole,
which also determined an increase in exercise time up to echocardiographic positivity
(placebo 5 385.9 6 51.4 vs. dipyridamole 5 594.4 6 156.9 s, p , 0.01).
CONCLUSIONS Low-dose dipyridamole infusion increases exercise tolerance in chronic stable angina, possibly
by endogenous adenosine accumulation acting on high affinity A1 myocardial receptors
involved in preconditioning or positively modulating coronary flow through collaterals. (J
Am Coll Cardiol 2000;35:83–8) © 1999 by the American College of Cardiology
Adenosine is a recognized mediator of myocardial precon-
ditioning (1,2). It acts on high affinity subtype A1 of
adenosine myocardial receptors which enhances the inhib-
itory G protein responsiveness, determining a protection
against ischemia by promoting the protein-kinase C activa-
tion (3,4) and opening of the ATP-dependent K1 channel
(5). However, clinical experience has shown that adenosine
accumulation is a double-edged sword for ischemic myo-
cardium, with definite dose-dependent ischemic potential
(6,7). At high doses, adenosine stimulates low affinity A2
coronary receptors, which are thought to mediate arteriolar
relaxation, and thereby malignant coronary vasodilation and
eventually myocardial ischemia in the presence of steal-
prone coronary anatomy (8,9). Dipyridamole determines
endogenous adenosine accumulation via inhibition of cellu-
lar reuptake (6). High intravenous doses determine a four-
fold increase in plasma adenosine (10) and have a clear
pro-ischemic effect—exploited for diagnostic testing with
functional imaging (11). On the contrary, very low doses
and prolonged infusion of intravenous dipyridamole induce
only a mild increase in plasma adenosine concentration (12).
We hypothesized that this mild stimulation by adenosine
achieved with low dose dipyridamole infusion might exert
an anti-ischemic effect in patients with exercise-induced
ischemia, conceivably through a predominant stimulation of
high affinity A1 myocardial receptors (2,13). We therefore
evaluated the effects of low-dose dipyridamole premedica-
tion in 10 patients with stable angina, exercise-induced
ischemia and angiographically assessed coronary artery dis-
ease (CAD) (or previous myocardial infarction [MI]), in a
randomized, double-blind, placebo controlled, crossover
study design. Exercise-induced ischemia was evaluated by
assessing effort-induced chest pain as a tertiary end point,
electrocardiographic changes as a secondary end point and
regional wall motion abnormalities by two-dimensional
echocardiography as a primary end point.
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METHODS
Patients. Ten men (63.4 6 7.3 years) with chronic stable
angina and abnormal exercise test limited by angina with
clear-cut horizontal or downsloping ST segment depression
($0.15 mV) and obvious echocardiographic positivity (aki-
nesia of $2 adjacent segments that were normally contract-
ing in resting condition) were selected. Patient characteris-
tics are reported in Table 1. All patients had CAD proved
by angiography with visually assessed $75% luminal diam-
eter narrowing in at least one major artery. Six patients had
one vessel and four patients had two-vessel disease; none
had three-vessel disease or significant left main narrowing.
Patients were excluded if they had collateral vessels at the
coronary angiography, MI within three months, unstable
angina, chronic left or right bundle branch block, symptom-
atic congestive heart failure, complex ventricular arrhyth-
mias, nonsinus rhythm, valvular heart disease or technically
poor acoustic window. An additional inclusion criteria
required all patients to be off calcium antagonists and
beta-adrenergic blocking agents (stopped $3 days before
testing) and have at least two reproducible (,15% variability
in exercise time) positive exercise stress tests in the previous
week (14). All patients gave written, informed consent for
the study.
Study design. Patients were studied in the morning in the
fasting state. They performed two exercise stress tests on
two nonconsecutive days with a 48 h interval between the
two tests. Before each exercise stress test, they received in a
double blind fashion, dipyridamole (15 mg in 30 min,
administered in microboluses of 1 mg every 2 min) or
corresponding placebo, which were randomly allocated in a
crossover study design.
Exercise stress test. All patients performed two multistage
bicycle ergometer tests, with an initial load of 25 W and
subsequent increments of 25 W every 2 min (14). Electro-
cardiographic leads showing the most obvious ischemic
changes during the previous exercise stress tests were con-
tinuously monitored during exercise. Twelve-lead electro-
cardiogram and systolic and diastolic pressures, obtained by
a cuff sphygmomanometer, were recorded at baseline and
each minute thereafter. Criteria for interrupting the test
were moderately severe chest pain, 0.2 mV of ST segment
depression 0.08 after the J point or maximal age-related
heart rate and muscular exhaustion in the absence of
ischemia (14). In this study, the heart rate-pressure product
(heart rate 3 systolic blood pressure 3 1/100) was used as
an index of heart work and measured at the onset of
ischemia (arbitrarily fixed at 0.10 mV of ST segment
depression) or at peak exercise in negative tests. Two-
dimensional echocardiographic monitoring was also per-
formed during exercise stress test with a commercially
available imaging system (ATL UltraMark 9, Bothell,
Washington). At baseline, peak stress and recovery phase
(3 min after stopping exercise with patient in the supine
position) the wall motion score index (WMSI) was calcu-
lated by using a 16 segment model of the left ventricle, each
segment scored from 1 5 normal to 4 5 dyskinetic
according to the recommendations of the American Society
of Echocardiography (15). To avoid the bias of the inter-
observer variability in stress echo reading (16,17), the same
experienced observer reviewed and scored each and every
stress study being blinded to the study condition (placebo vs.
dipyridamole). The intra- and interobserver reproducibility
of the stress echo reading in our lab is .90%. For each
study, the following data were analyzed: 1) WMSI at rest,
peak and recovery, and 2) exercise-time as the interval
(seconds) between starting of exercise and appearance of
obvious dyssynergy (change in wall motion score .0.20
from baseline).
Statistical analysis. Data are expressed as mean 6 1
standard deviation. Continuous variables before and imme-
diately after infusion of placebo or dipyridamole were
compared using a paired Student t test and Wilcoxon test
for nonparametric data. Analysis of echocardiographic, er-
gometric and hemodynamic variables during exercise-stress
echo after pretreatment with placebo or dipyridamole was
performed using a two-way repeated measures analysis of
variance. Post hoc comparisons between groups at various
time points were performed with Student t test for unpaired
data with Bonferroni correction (18). Categorical variables
were compared with chi-square test and Fisher exact test
when appropriate. We considered as significant a two-tailed
p value ,0.05.
RESULTS
Resting conditions. Table 1 summarizes the clinical char-
acteristics of the study population. Hemodynamic, echocar-
Abbreviations and Acronyms
CAD 5 coronary artery disease
MI 5 myocardial infarction
WMSI 5 wall motion score index
Table 1. Study Population
Number of patients 10
Age (yrs) 63.4 6 7.3
Weight (kg) 79.6 6 13.2
Height (cm) 173.2 6 4.7
BSA (m2) 1.93 6 0.13
Risk factors
Hypertension (number) 6
Previous AMI (number) 3
Diabetes (number) 2
Dyslipidemia (number) 9
Smokers (number) 5
AMI 5 acute myocardial infarction; BSA 5 body surface area.
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diographic and electrocardiographic parameters before and
after infusion with placebo and dipyridamole are summa-
rized in Table 2. Neither placebo nor dipyridamole infusion
induced significant changes in heart rate, systolic and
diastolic blood pressure or rate-pressure product compared
with the preinfusion control. The heart rate-corrected QT
interval (ms) and WMSI did not change as well after
pharmacological pretreatment.
Exercise testing. All patients had technically adequate
resting, effort and recovery ECG tracing as well as echocar-
diographic images. At peak effort, after pretreatment with
placebo, all patients exhibited a score of ST segment
depression (defined as sum, in mm, of the ST segment
depression in all the leads with a positive electrocardio-
graphic response) of 4.8 6 1.3 mm at a mean load of 90 6
12 W, associated with the appearance of anginal chest pain
Table 2. Effects of Placebo and Dipyridamole (15 mg in 30 min) on Hemodynamic, Echocardiographic and
Electrocardiographic Parameters
Test 1 Test 2
Basal Placebo p Basal Dipyridamole p
SBP (mm Hg) 139.5 6 14.2 138.5 6 14.5 0.34 135.5 6 14.2 133 6 8.4 0.61
DBP (mm Hg) 86.5 6 9.4 84.5 6 11.4 0.10 82.5 6 10.8 81.5 6 8.2 0.59
HR (beats/min) 81.5 6 8.3 81.8 6 6.7 0.71 80.2 6 10.8 83.5 6 9.7 0.06
RPP 11370 6 1690.9 11323 6 1500.1 0.81 10849 6 1739 11042 6 1654.2 0.71
QTc 0.41 6 0.02 0.41 6 0.02 1.0 0.40 6 0.01 0.41 6 0.03 0.33
WMSI 1.07 6 0.07 1.07 6 0.07 1.0 1.07 6 0.07 1.07 6 0.07 1.0
HR 5 heart rate; RPP 5 rate pressure product; QTc 5 heart rate-corrected QT interval (ms); SBP 5 systolic blood pressure; WMSI 5 wall motion score index.
Table 3. Results of Exercise Stress Echocardiography After Placebo and Dipyridamole in the Total Population
Pt (mm)
Number
Watt to
Ischemia
Time to
Ischemia (s) WMSI
Recovery
(s) RPP
Score
ST PeakST Dyss. ST Dyss. R P ST Dyss. R P
After Placebo
1 75 75 335.4 330 1.0 1.75 600 480 10,800 25,400 5
2 100 100 451.2 443.4 1.13 1.50 480 480 9,360 24,510 4
3 75 75 334.8 324 1.0 1.38 420 300 13,760 21,280 7
4 100 100 450 438 1.13 1.63 420 360 10,320 18,180 3
5 100 100 455.4 435 1.0 1.38 660 540 11,050 19,890 6
6 100 100 480 443.4 1.0 1.25 240 240 13,440 25,920 4
7 100 100 391.8 372 1.13 1.50 480 360 13,950 24,890 5
8 75 75 378 369 1.13 1.75 420 300 9,880 16,830 5
9 100 100 450 385.8 1.19 1.63 360 360 10,500 22,600 3
10 75 75 331.2 318 1.0 1.75 420 420 10,640 20,160 6
Mean 90 90 405.8 385.9 1.07 1.55 450 384 11,370 21,966 4.8
6SD 12 12 58.2 51.4 0.07 0.17 117 94 1,690 3,190 1.3
After Dipyridamole
1 125 100 504 453 1.0 1.38 600 480 9,750 31,175 5
2 125 125 514.8 514.8 1.13 1.31 180 120 11,400 27,600 2
3 125 125 570 564 1.0 1.19 180 120 12,710 28,980 2
4 175 175 882 840 1.13 1.13 0 0 12,040 25,200 0
5 150 125 605.4 570 1.0 1.13 480 360 11,900 25,155 3
6 125 125 545.4 513.6 1.0 1.13 300 240 12,040 27,900 2
7 150 150 762 720 1.13 1.13 0 0 12,740 31,900 0
8 75 100 330 372 1.13 1.50 180 180 8,760 16,830 2
9 175 175 840 840 1.19 1.19 0 0 8,470 27,940 0
10 125 125 570 556.8 1.0 1.63 120 120 8,680 21,160 4
Mean 135 132.5 612.4 594.4 1.07 1.27 204 162 10,849 26,284 2.0
6SD 29 26 168.6 156.9 0.07 0.17 204 178 1,739 4,703 1.7
p value* ,0.0001 ,0.001 ,0.01 ,0.01 NS ,0.01 ,0.01 ,0.01 NS ,0.01 ,0.01
*p values comparing first and second exercise echocardiography test. Dyss. 5 dyssynergy; R 5 rest; P 5 peak; Pt 5 patients; WMSI 5 wall motion score index.
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of variable intensity and duration (Table 3). Wall motion
abnormalities appeared in all patients, involving 6.4 6 2.7
myocardial segments with a mean WMSI of 1.55 6 0.17. In
comparison with placebo, pretreatment with dipyridamole
demonstrated a significant increase in seconds of exercise
until 0.1 mV of ST segment depression (612.4 6 168.6 vs.
405.8 6 58.2 s, p , 0.01) or until echocardiographic
positivity (594.4 6 156.9 vs. 385.9 6 51.4 s, p , 0.01)
(Table 3 and Fig. 1). Watts to positivity were also signifi-
cantly higher after dipyridamole than placebo (135 6 29 vs.
90 6 12, p , 0.001) as well as the rate-pressure product
(26,284 6 4,703 vs. 21,966 6 3,190, p , 0.01) expressing
a higher heart work necessary to reach an ischemic thresh-
old. During exercise-stress echo performed after pretreat-
ment with dipyridamole, angina appeared in only two
patients (p , 0.001 vs. pretreatment with placebo) and was
also less severe. The exercise stress test was, moreover,
completely negative in three patients who reached the 85%
of predicted heart rate without appearance of angina, ST
segment depression or wall motion abnormalities at the
echocardiographic monitoring. Considering the primary
end point of exercise-stress echo, exercise induced wall
motion abnormalities were less severe after dipyridamole
when compared with placebo, with a mean WMSI of
1.27 6 0.17 (vs. 1.55 6 0.17 of placebo, p , 0.01) and more
rapidly recovering (162 6 178 vs. 384 6 94 s, p , 0.01)
(Fig. 2).
DISCUSSION
Low dose, prolonged dipyridamole infusion, at a dose
known to increase plasma adenosine levels only modestly,
increases work tolerance and ischemic threshold in patients
with stable effort angina and angiographically assessed
CAD.
Pathophysiological mechanisms. At least in theory, sev-
eral mechanisms might concur to the beneficial effect of
dipyridamole, including preconditioning, increase in coro-
nary collateral blood flow and metabolic cardioprotection.
The principal receptor target of low dose dipyridamole
infusion is A1 receptor present on the myocardium and
known to comediate preconditioning. The high affinity for
adenosine can explain why it can be activated also by a
dipyridamole dose known to increase plasma adenosine only
modestly over resting level (12). With higher and faster
dipyridamole infusion rates, as those used for stress testing
purposes, plasma adenosine concentration increases more
substantially, with values three- to four-fold higher than
those present at rest (10). Such adenosine concentration is
effective in stimulating low affinity A2 receptors present in
coronary vessels. In particular, stimulation of A2a receptors
produces marked dilation of coronary resistance vessels,
determining arteriolar vasodilation and frequent occurrence
of steal phenomena in the presence of significant CAD.
This heterogeneity of populations of adenosine receptors
may explain why a beneficial anti-ischemic effect of the
drug is detectable at low doses and a clear detrimental
pro-ischemic effect appears at high doses in unselected
Figure 1. Time (in seconds—ordinal axis) of appearance of wall
motion abnormalities at the echocardiographic examination (bot-
tom panel) and of ST segment shift ($1 mm) at ergometer test
(top panel) after pretreatment with placebo and dipyridamole.
Each line represents individual values. Low-dose dipyridamole
infusion increases exercise tolerance in chronic stable angina
pectoris.
Figure 2. Wall motion score index at rest, peak of exercise stress
echo and at 3 min of recovery after pretreatment with placebo
(white box) and dipyridamole (black box). Wall motion abnor-
malities after dipyridamole were significantly less severe and more
rapidly recovering in comparison with placebo.
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patients (6,7). Adenosine is known to increase coronary
blood flow in patients with spontaneously visible collaterals,
as a result of a reduction in the coronary collateral vascular
resistance and peripheral vascular resistance of the recipient
vessel (19,20). With high dipyridamole doses, angiographi-
cally assessed coronary collateral circulation represents a
steal-prone coronary anatomy favoring the induction of
ischemia during vasodilator stress testing (21). In our study,
we excluded patients with collateral vessels at the coronary
angiography, but this selection criterion does not rule out
the anatomic presence and functional relevance of coronary
collaterals. In fact, Cohen and Rentrop (22) showed that
coronary collaterals could be demonstrated during coronary
occlusion even if they were not evident during routine
baseline coronary angiography. It is conceivable that low
dose dipyridamole might increase coronary flow through
collaterals (19,20). An additional possibility is a metabolic
effect of adenosine. In fact, adenosine increases glucose
uptake independent of its vasodilatory effect and stimulates
glycolytic flux in anoxic myocardium (23,24). Which, if any,
of the three pathways (preconditioning, coronary hemody-
namic, cardiometabolic effect) is more relevant in determin-
ing the beneficial effects of dipyridamole cannot be estab-
lished from this study.
Comparison with previous studies. Several studies have
shown the protective effects of dipyridamole or exogenous
adenosine in human models of myocardial ischemia, mostly
with intracoronary injection during coronary angioplasty
(25–27). Bamiphylline is an A1 adenosine receptor blocker
that abolishes preconditioning due to repeated episodes of
ischemia, again suggesting that adenosine A1 receptor
stimulation may be important to prevent ischemia (28).
Laghi-Pasini et al. (12) convincingly showed that peripheral
infusion of low-dose dipyridamole prevents dipyridamole-
induced ischemia detected during pharmacological stress
echo, clearly demonstrating the two faces of dipyridamole in
the very same patient in the same setting: dipyridamole is
anti-ischemic and protective at very low dose and pro-
ischemic and detrimental at high doses. Our study moves
along the same line, since we used a “therapeutic” dosage
and infusion schedule similar to the one proposed by
Laghi-Pasini et al. (12). However, our study is also basically
different, since we evaluated the “therapeutic” effect of
dipyridamole on a physiological model of exercise-induced
ischemia.
The integrated anti-ischemic adenosine strategy. Aden-
osine has been named a “retaliatory metabolite” (29) acting
to protect from ischemia the very same cells that produce it.
A1 receptors are a first line, short-acting, functional line of
defense of adenosine accumulation against acute ischemia.
This response temporally overlaps with an A1–A2 receptors
mediated second line, long-acting, structural line of defense
exerted by adenosine accumulation against chronic ischemia
via coronary angiogenesis (30). Such a “cardiovascular”
anti-ischemic system might be important not only in the
cardiac, but possibly also at the cerebrovascular level (31).
Further studies are needed to explore the far reaching
implications of this hypothesis.
Study limitations. The main limitation of our study was
the small number of patients studied. However, although
only 10 subjects were studied, the power of the investigation
was substantially increased by using each subject as his own
control in a double-blind crossover design in which dipyr-
idamole was compared with placebo. Another limitation
was the lack of determination of plasma adenosine levels.
The absence of electrocardiographic signs of ischemia after
infusion with dipyridamole showed the absence of clear-cut
ischemic effect of the drug, so that the plasma and intersti-
tial adenosine levels reached in our patients by low dose,
prolonged dipyridamole infusion were likely unable to
induce a steal phenomena in the coronary circulation. On
the other hand, Laghi-Pasini et al. (12), using a lower dose
of intravenous dipyridamole (2 mg every 30 min for five
consecutive times) have recently demonstrated a pulsed
increase in plasma adenosine levels to determine a cardio-
protective effect during a subsequent dipyridamole stress
test. The design of our study does not allow clarification of
the underlying mechanism of the anti-ischemic effect ob-
served with low dose dipyridamole. A1 receptor-mediated
preconditioning, increase in coronary blood flow (through
collaterals?) and metabolic cardioprotection through poten-
tiation of the glycolytic pathway are all reasonable but
unproven candidates.
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